Mirtazapine for Sleep Disorders in Alzheimer's Disease

Last updated: June 3, 2013
Sponsor: Brasilia University Hospital
Overall Status: Trial Status Unknown

Phase

3

Condition

Sleep Disorders

Alzheimer's Disease

Dementia

Treatment

N/A

Clinical Study ID

NCT01867775
052/2012
  • Ages > 55
  • All Genders

Study Summary

The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.

Eligibility Criteria

Inclusion

Inclusion Criteria: Fifty-five years of age or older; Diagnosis of probable Alzheimer's disease by NationalInstitute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Diseaseand Related Disorders Association criteria; Hachinski Ischemia Scale score less than 5Mini-Mental State Examination score of O to 26 Actigraph evidence of a mean time immobileof less than 7 hours per night based on at least 7 nights of complete actigraph datacollected over a single week; For-week history of sleep disorder behaviors, occurring atleast once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI)Nighttime Behavior scale; Sleep disturbance observed was not present before the diagnosisof AD; Other co-morbidities, especially delirium, depression, chronic pain and medicationuse may be present, but do not cooperate in the primary symptoms; Computed tomography ormagnetic resonance imaging since the onset of memory problems showing no more than 1lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or otherintracranial disease or normal; Stable medications for 4 weeks prior to the screeningvisit; Having a mobile upper extremity to which to attach an actigraph; Residing with aresponsible spouse, family member, or professional caregiver who is present during thenight and would agree to assume the role of the principal caregiver for the 3-weekprotocol; Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion

Exclusion Criteria: Sleep disturbance associated with an acute illness, delirium or psychiatric disease;Clinically significant movement disorder, such as akinesia, that would affect actigraphicdifferentiation of sleep and wakefulness Severe agitation; Unstable medical condition;Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit;Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of theprotocol; Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day,and only 1 alcoholic drink after 6:00 PM for the duration of the protocol; Prior use ofmirtazapine for the treatment of sleep disturbances; Caregiver deemed too unreliable tosupervise the wearing of the actigraph, to administer trazodone the proper time, tomaintain tbe sleep diary, or to bring the patient to the scheduled visits;

Study Design

Total Participants: 30
Study Start date:
May 01, 2012
Estimated Completion Date:
May 31, 2014

Study Description

Mirtazapine has been used for depressed elderly with sleep disorders with good tolerability and efficacy. The study hypothesis is that mirtazapine could also be used in demented with sleep disorders.

Sleep disorders (SD) affects 35 to 50 percent of patients with Alzheimer Disease (AD). These disorders often make caring for patients at home very difficult and It's also associated with higher risk of institutionalization and increases health care costs. Treatment of SD in people with dementia may benefit both patients and their caregivers. However, little is known about the efficacy of pharmacological treatments for treating sleep disturbances in AD.

Connect with a study center

  • Brasilia University

    Brasilia, Distrito Federal 70840
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.